With direct letters, regulatory comments and other activities, Vizient strives to form constructive relationships with lawmakers, regulatory agencies and administration officials, to provide a unified voice on issues that have a direct impact on our members.

2025 Advocacy

May 7 – Vizient comments to the Department of Commerce regarding the imports of pharmaceuticals and pharmaceutical ingredients and their derivative products

April 14 - Vizient comments to the Assistant Secretary for Technology Policy (ASTP) on the United States Core Data for Interoperability (USCDI) Draft Version 6

March 18 – Vizient comments to the Drug Enforcement Administration (DEA) on the Special Registrations for Telemedicine and Limited State Telemedicine Regulations proposed rule

March 7 – Vizient comments to the HHS Office of Civil Rights on the proposed Health Insurance Portability and Accountability Act (HIPAA) Security Rule to Strengthen the Cybersecurity of Electronic Protected Health Information (ePHI)

March 4 - Vizient letter to the President and Secretary of Homeland Security regarding recently enacted tariffs on products imported from Canada, Mexico and China

February 24 - Vizient letter to congressional leadership urging permanent or long-term access to telehealth services

February 4 - Vizient letter to the President and Secretary of Homeland Security regarding recently announced tariffs on products imported from Canada, Mexico and China

January 27 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program proposed rule

Connect with Vizient to help you solve health care’s biggest challenges

Contact us